MPG.eBooks - Description: CADTH Canadian drug expert committee recommendation (final): Certolizumab pegol (Cimzia -- UCB Canada Inc.)

Cover Image

CADTH Canadian drug expert committee recommendation (final): Certolizumab pegol (Cimzia -- UCB Canada Inc.) indication : treatment of adult patients with moderate-to severe plaque psoriasis who are candidates for systemic therapy

The CADTH Canadian Drug Expert Committee (CDEC) recommends that certolizumab pegol (CZP) be reimbursed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy if certain conditions are met

Bibliographic Details
Corporate Authors:	CADTH Canadian Drug Expert Committee, Canadian Agency for Drugs and Technologies in Health
Format:	eBook
Language:	English
Published:	Ottawa (ON) Canadian Agency for Drugs and Technologies in Health November 2019, 2019
Edition:	Version: 1.0
Series:	CADTH common drug review
Subjects:	Insurance, Health, Reimbursement Adult Certolizumab Pegol / Therapeutic Use Canada Cost-benefit Analysis Certolizumab Pegol / Economics Immunosuppressive Agents / Therapeutic Use Psoriasis / Drug Therapy
Online Access:
Collection:	National Center for Biotechnology Information - Collection details see MPG.ReNa

Description
Summary:	The CADTH Canadian Drug Expert Committee (CDEC) recommends that certolizumab pegol (CZP) be reimbursed for the treatment of adult patients with moderate-to-severe plaque psoriasis who are candidates for systemic therapy if certain conditions are met
Physical Description:	1 PDF file (10 pages)